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Host-oriented therapeuticsConventional approaches for therapeutic targeting of viral pathogens have consistently faced obstacles
arising from the development of resistant strains and a lack of broad-spectrum application. Inﬂuenza
represents a particularly problematic therapeutic challenge since high viral mutation rates have often
confounded many conventional antivirals. Newly emerging or engineered strains of inﬂuenza represent an
even greater threat as typiﬁed by recent interest in avian subtypes of inﬂuenza. Based on the limitations
associated with targeting virally-encoded molecules, we have taken an orthogonal approach of targeting host
pathways in a manner that prevents viral propagation or spares the host from virus-mediated pathogenicity.
To this end, we report herein the application of an improved technology for target discovery, Random
Homozygous Gene Perturbation (RHGP), to identify host-oriented targets that are well-tolerated in normal
cells but that prevent inﬂuenza-mediated killing of host cells. Improvements in RHGP facilitated a thorough
screening of the entire genome, both for overexpression or loss of expression, to identify targets that render
host cells resistant to inﬂuenza infection. We identify a set of host-oriented targets that prevent inﬂuenza
killing of host cells and validate these targets using multiple approaches. These studies provide further
support for a new paradigm to combat viral disease and demonstrate the power of RHGP to identify novel
targets and mechanisms.
© 2009 Elsevier Inc. All rights reserved.IntroductionInfection with inﬂuenza virus causes a highly contagious disease
of the respiratory tract. In an average year, inﬂuenza infects millions
worldwide and, in the United States, is responsible for hundreds of
thousands of hospitalizations and 20,000–30,000 deaths (Thompson
et al., 2003). The primary prevention modality for inﬂuenza consists
of a vaccine against strains of inﬂuenza that are predicted to infect
the population in the coming season and the primary antibody
response of these vaccines is directed towards variability in the
hemagglutinin (HA) and neuraminidase (NA) antigens. Since
inﬂuenza virus can change within a single season by the processes
of antigenic drift and shift, the efﬁcacy of annual vaccination can be
circumvented. Thus, the value of the annual vaccine ﬂuctuates
depending on the similarity of the vaccine strain and the circulating
inﬂuenza strain. In a single-center analysis by the CDC, the estimated
clinical effectiveness of the inﬂuenza vaccine during the 2007–2008
season was limited to 44% of those vaccinated (Belongia et al., 2008).
Compounding this, recent surveys indicate that less than one third of
American adults opt for seasonal immunization. Consequently, inﬂuenza.S. Kinch).
ll rights reserved.is anticipated to remain a prominent and persistent cause of morbidity
and mortality.
Once an individual is infected with inﬂuenza, therapeutic options
are limited to supportive care or a handful of medications that target
viral pathways, primarily neuraminidase (Luscher-Mattli, 2000; Ong
and Hayden, 2007). However, the wide application of traditional
antiviral medications has favored the emergence of drug-resistant
viruses, thereby presenting a major new challenge to the control of
infectious diseases. Compounding the increasing problems with
seasonal inﬂuenza, much recent attention has focused on emerging
pandemic strains of inﬂuenza and the potential that genetically-
modiﬁed inﬂuenza could provide an effective tool for bioterrorism.
The public health and economic impacts of such drug-resistant or
non-traditional inﬂuenza variants could be devastating, thus spurring
the need for new paradigms to target inﬂuenza.
One new approach for addressing viral infection is to target host
factors that are essential to the pathogenesis of viral disease (Fox,
2007; Tan et al., 2007). A prominent example from the war on HIV/
AIDS is the development of antagonists of CCR5 (Reeves and Piefer,
2005; Wheeler et al., 2007). These antagonists seek to prevent the
function of a surface-exposed co-receptor that is necessary for the HIV
binding and internalization. Early ﬁndings suggest these agents may
provide much-needed options for the treatment of the subset of
patients infected with CCR5-trophic HIV-1 viruses.
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and host factor proteins (Lamb and Takeda, 2001). Productive
infection of the inﬂuenza virus requires the cooperation of host
proteins for virtually every step of the life cycle, including entry and
internalization, uncoating of nucleic acid, genome replication, protein
translation, transportation, and processing, as well as virus assembly
and late budding (Ahlquist et al., 2003; Chen and Lamb, 2008; Ludwig
et al., 1999). Based on these ﬁndings, our laboratory and others have
begun to consider host targets for antiviral therapy. Recent studies
utilized small interference RNA (siRNA) approach to identify host
factors involved in the early viral infection with inﬂuenza (Hao et al.,
2008), HIV (Brass et al., 2008; Konig et al., 2008) or West Nile virus
(Krishnan et al., 2008). Although intriguing, siRNA is intrinsically
limited to known sequences and efﬁcient siRNA delivery into the host
cells, which often limits the efﬁciency of these approaches.
Our laboratories have been pioneering a new approach to sample
any gene in a eukaryotic cell that can control cellular processes of
interest to the investigator. Originally known as RandomHomozygous
Knockout (RHKO), the initial approach was developed to overcome
barriers arising from the fact that eukaryotic cells generally have two
sets of chromosomes (Li and Cohen, 1996). For example, the diploid
nature of mammalian cells had precluded simple knock-out based
evaluation of target genes that have proven to be so powerful in our
understanding of bacterial pathways. The improvements provided by
RHGP include the ability to simultaneously knockdown both copies of
any target gene, independent of any prior knowledge or annotation of
that gene. Herein, we report on the application of an improved form of
RHGP, which can also cause up-regulation of any target in the cell,
including whole genes or individual domains. Consequently, RHGP
provides a means to interrogate the entire genome for any genetic
change that is causative of the phenotype under investigation. We
apply RHGP to identify and validate a set of host-oriented targets that
are required for inﬂuenza infection.Fig. 1. Schematic overview of the RHGP gene search vector. (A) An overview of the pRHGP2
facilitate the RHGP-based identiﬁcation of host-based targets. Note that the RSV E/P of the GS
outcomes of GSV integration into the genome. The left panels demonstrate how integration
facilitate overexpression of an antisense to disrupt the second allele. On the other hand,
overexpression of the entire target gene (or domains thereof). Note that the phenotype is tig
the phenotype by turning the GSV vector “off” when cells are cultured in the presence of DResults
Construction of the RHGP cellular library
The central feature of RHGP is a unique lentiviral-based genetic
element, known as a gene search vector (GSV), which was designed to
interrogate the entire genome and identify targets that allow host
cells to resist or survive infection with inﬂuenza virus. Our experi-
mental strategy centered upon integration of the GSV at a single site in
the genome, where it regulated expression of the target gene via an
inducible promoter (Fig. 1A). The vector encoded for a self-inactivat-
ing lentiviral LTR, which prevented the GSV from re-emerging from a
transduced cell. The RSV E/P promoter was used only for production
of the GSV and was eliminated by the integration of the GSV into the
host genome.
The GSV could integrate in either a sense or an antisense
orientation. In the antisense conﬁguration, the integration event itself
inactivated one allele and facilitated expression of an antisense
construct, which knocked down genes encoded on the other allele
(Fig. 1B, left panels). In this way, RHGP facilitated homozygous
perturbation of both gene copies in diploid cells. In the opposite
(sense) orientation, RHGP facilitated overexpression of the target
gene (Fig. 1B, right panels). This outcome could extend beyond simple
overexpression of an entire gene (e.g., insertion upstream of the start
site) since integration downstream of the start site could trigger
overexpression of domains, which could produce a dominant-
negative inhibitor of wild-type gene function. As such, RHGP allowed
us to interrogate the entire cell genome to identify different types of
events that allow host cells to resist or survive inﬂuenza infection.
To facilitate RHGP, a library of MDCK cells was transduced using a
lentiviral-based GSV. As the average gene size in the genome is
estimated to be 27 kb (Gupta and Varshney, 2004), we calculated that
105 independent integration events would ensure random coverage of2 gene search vector (GSV) is shown, highlighting important features of the vector that
V is lost after the integration into the host genome. (B) Shown is an overview of potential
of the gene search vector in an “antisense orientation” would disrupt Allele 1 and then
the right panels demonstrate how integration in a sense orientation would facilitate
htly regulated by the Tet-inducible promoter, thus allowing the investigation to reverse
oxycycline.
475B. Sui et al. / Virology 387 (2009) 473–481the entire genome (Li and Cohen, 1996). As outlined in the Materials
and methods, pRHGP22 was constructed using an expression cassette
consisting of a pTRE-Tight-CMV promoter driving a blasticidin
resistance gene, which provided a selectable marker under strict
inducible control. The library of transduced host cells was then
selected using blasticidin and surviving cells were screened for
inﬂuenza resistance as detailed below.
Screening the inﬂuenza virus resistant phenotypes
To identify targets that render host cells resistant to inﬂuenza, an
RHGP library was generated in MDCK cells and inﬂuenza challenge
performed as outlined in Fig. 2. This particular cell model was selected
based on its well-established responsiveness to inﬂuenza infection
and because the canine genome has been annotated and can be
compared with human homologues. We conducted preliminary
studies to ensure that MDCK cells were efﬁciently and entirely killed
by A/Udorn/72 under the conditions utilized for selection. This
outcome was essential to ensure that surviving cells arose as a result
of the RHGP perturbation and not as an artifact of spontaneous
resistance to inﬂuenza. Following library construction with the
pRHGP22 GSV, a library consisting of at least 107 independentFig. 2. Schematic overview of the strategy to identify host genes necessary for inﬂuenza
infection. Shown is an overview of the experimental strategy used to identify relevant
targets. Following transduction with the RHGP vector and antibiotic selection to
establish an “RHGP library” of perturbations, the host cells are challenged with a lethal
infection from inﬂuenza virus. Once cloned, inﬂuenza-resistant survivors were
validated by reversing the RHGP phenotype in the presence of Doxycycline. The
genomic DNA is then isolated from those clones that demonstrate reversible, RHGP-
dependent survival and the identity of the target gene, along with the orientation of the
GSV integration event (“Sense” or “Antisense” is then determined).MDCK clones was created to ensure 100-fold coverage of the genome.
A lowMOI (0.1) was employed during the library creation to minimize
the transduction of any cell by more than one different GSV. As an
additional means of conﬁrming GSV integration, the MDCK library
was incubated with a lethal concentration of blasticidin (administered
48 h post-infection).
The library was challenged by infection with inﬂuenza A/Udorn/
72 to select for inﬂuenza-resistant cells. We had previously estab-
lished that infection with A/Udorn/72 (MOI of 10−1) reproducibly
killed all MDCK cells within 48 h (not shown). As a control, parallel
cultures of mock-transduced cells were treated identically and no
survivors were observed after 48 h. We further sought to minimize
artifacts by subjecting surviving cells to multiple rounds of lethal
challenge. Thus, the samples were subjected to at least three rounds of
inﬂuenza challenge, at which time no surviving cells were detected in
any of the matched controls (not shown).
In the course of these studies, we considered that challenge at a
high relative MOI of inﬂuenza might bias for certain types of targets.
For example, survival at a high MOI might unintentionally favor
targets associated with early stages of infection or bias against targets
associated with later stage events. To preclude such bias, a parallel
series of studies were conducted to compare survival in the context of
viral challenge at low titer. For this, the clones were subjected to
infection at low initial MOI (MOI of 10−5). The cultures were then
evaluated over time and using multiple rounds of infection to ensure
that all cells in the control samples had been killed by inﬂuenza (see
Fig. 3 for an example).
After selecting for RHGP-transduced cells that survived challenge
with inﬂuenza, clones were isolated by single cell cloning and
expanded, yielding an average of 3000 clones per experiment. Given
the abundance of clones, a subset of 303 different inﬂuenza-resistant
clones (10% of the total population) was selected at random and
subjected to a second round of single cell cloning to ensure clonality
(Table 1). These subclones were then subjected to a battery of studies
to conﬁrm the phenotype and identify the target genes. Each subclone
was tested again for the ability to survive a lethal challenge with
inﬂuenza. Parental MDCK host cells that had been transduced with an
inactive Tet-off GSV provided a matched negative control. 129
different subclones (43% of the initial population) were isolated
based on their ability to survive lethal challenge with inﬂuenza (see
the “−Dox” samples in Fig. 3A for representative examples of
inﬂuenza-resistant clones). Most of the down-selection at this stage
resulted from colonies that failed to survive the single cell cloning
process.
Reversibility assay of the virus resistant clones
A key feature of the RHGP technology is the ability to validate
candidate targets via regulation by an inducible promoter. This
allowed us to eliminate candidates that might have become resistant
to inﬂuenza as a result of spontaneous mutation or other artifacts not
related to RHGP. Since the promoter for the RHGP vector was under
control of a Tet-off system, we compared inﬂuenza-mediated killing of
the candidates in the presence or absence of Doxycycline. This study
conﬁrmed that 111 of the 129 surviving clones (86%) demonstrated
reversible resistance to inﬂuenza challenge (see Figs. 3A and B for
representative ﬁndings of a reversible phenotype). The remaining 18
clones (14%) were de-prioritized to ensure that RHGP, and not
unrelated artifacts, was responsible for the inﬂuenza-resistant
phenotype.
Identiﬁcation of the host gene by genomic DNA cloning
The RHGP gene search vector was designed to efﬁciently locate
target genes and determine the orientation (sense or antisense) of the
integration event. Speciﬁcally, the gene search vector encodes for an
Fig. 3. Validation of inﬂuenza virus resistant subclones with reversibility assay. Two representative RHGP subclones were challenged with a lethal infection of A/Udorn/72 inﬂuenza
virus for 48 h in the absence “Promoter On” or presence “Promoter Off” of Doxycycline. The survival of infected cultures was assessed visually using crystal violet to stain viable,
attached cells. All experiments were conducted at a relatively (A) low titer (10−5 pfu/mL) or (B) high titer (10−1 pfu/mL) to preclude bias towards targets associated with the early
or late stages of the viral life cycle.
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based genomic DNA cloning. Genomic DNA was isolated from the 111
clones that had demonstrated reversible resistance to inﬂuenza,
yielding a total of 110 target genes (Table 1). The resulting genomic
DNA sequences ﬂanking the RHGP vector insertion sites were
subjected to genome mapping against the canine genome using the
UCSC Genome Browser. Consistent with the experimental design,
most targets consisted of a single integration site per clone. We were
unable to isolate candidate genes from a small subset of candidates
due to technical limitations. In addition, a minority of samples
contained multiple integration events, which could have arisen as a
result of multiple RHGP integration sites or if the subclone had not
been clonal. Due to this ambiguity, the genes associated with multiple
integration events were de-prioritized for further validation.
The site and orientation of integration offered by RHGP provided
insight into the types of perturbations that allowed host cells to
survive challenge with inﬂuenza (Fig. 4). Speciﬁcally, the RHGP
perturbations were broadly divided into three groups: 1) “Antisense”:
Antisense integration events that facilitated disruption of one allele
and antisense inhibition of the other allele; 2) “Sense-Downstream”:
Integration in a sense orientation, which would be predicted to
facilitate production of one or more domains, which could act as a
dominant-negative inhibitor of the full-length gene product; and 3)Table 1
Summary of RHGP-based discovery of gene perturbations that render host cells
resistant to a lethal challenge with inﬂuenza virus.
Property Frequency
Inﬂuenza-resistant clones selected for continued investigation 303
Clones retaining inﬂuenza-resistant phenotype 129 of 303 (43%)
Clones validated via RHGP reversibility 111 of 129 (86%)
Targets Sequenced 110 of 111 (99%)
Targets with demonstrated links to viral infection 4 of 110 (4%)
Targets related to other genes with links to viral infection 23 of 110 (21%)
Targets with no known links to viral infection 83 of 110 (75%)
Targets not yet annotated 11 of 110 (10%)
Shown is an overview of the progression of events associated with the RHGP-mediated
identiﬁcation of host targets that allow host cells to resist an otherwise lethal infection
with inﬂuenza. Please note that the majority of speciﬁc targets (96%) and target families
(75%) identiﬁed using RHGP were unique. RHGP also facilitated identiﬁcation of targets
that had net been annotated.“Sense-Upstream”: Integration in a sense orientation upstream of the
start site, which could facilitate overexpression of the entire target
gene. Of the 99 known targets identiﬁed using RHGP, 56 targets (56%
of total targets) represented “Antisense” knockdown of target
expression. Another 35% of the targets represented “Sense-Down-
stream” events, likely conveying overexpression of dominant-negative
inhibitors of wild-type gene expression. Consistent with this inter-
pretation, we noted that one particular target, PTBP1, was indepen-
dently identiﬁed as a target in two separate clones; one clone in an
“Antisense” orientation and another in a “Sense-Downstream”
orientation. The remaining 9% represented “Sense-Upstream” inser-
tions. The orientation of 11 target genes (10% of the 110 targets
sequenced herein) could not be ascertained because the gene itself
had not been previously described and therefore assignment of
orientation was not possible.
In a separate assessment, we asked if these 110 target genes had
been linked previously with viral infection. Only four of the 110 targets
identiﬁed herein (MDN1, GRK6, AKT1 and STXBP1) had been directly
linked viral infection (Table 2), suggesting novel information about
106 targets (96%) identiﬁed using RHGP. By extending our analysis to
related proteins, we found that 23 of 110 targets (21%) identiﬁed
herein shared homology with or was a co-member of a superfamily
with, host targets that had been linked previously with viral infection.
These ﬁndings suggest RHGP identiﬁed novel functions for the
preponderance (75%) of the host targets. Two targets identiﬁed
herein (C4orf32 and C21orf33) had simply been described as open
reading frames (orfs), with no function ascribed. Altogether, these
ﬁndings suggest that RHGP-based interrogation of the host genome
had identiﬁed both novel targets and/or ascribed novel functions to
known genes.
Validation of target genes using naïve cells
RHGP identiﬁed a series of targets in MDCK cells that conferred
resistance to inﬂuenza infection and the reversibility of the phenotype
provided an initial validation for these targets. We then sought to
verify these candidates using an independent experimental system to
exclude outcomes that might arise as an artifact of the MDCK cells or
RHGP technology. Since the targets genes had been isolated from
canine-derived MDCK cells, we identiﬁed their human homologues
Fig. 4. Gene search vector integration and resultant perturbations of host targets. (A) Shown is a representation of possible orientations and sites of GSV integration into the genome
that arise during creation of the “RHGP library.” (B) An overview of the targets identiﬁed using RHGP that facilitate host cell resistance to lethal inﬂuenza challenge is shown. DNAwas
sequenced from genomic sequences using GSV-encoded primers and the resulting sequences were evaluated using the UCSC Genome Browser. Please note that “sense” integrations
downstream of the normal coding start site (ATG) might be anticipated to favor expression of dominant-negative inhibitors of wild-type target. Consistent with this idea, the PTBP1
target (bold) was isolated in independent clones both in an “antisense” as well as a “Sense-Downstream” orientation.
477B. Sui et al. / Virology 387 (2009) 473–481and expressed siRNAs selective for these targets in human HEK-293
cells.
A subset of targets was selected for independent validation in
HEK-293 cells. Due to the sheer volume and efﬁciency of targetsTable 2
Comparison of common families of host-oriented targets identiﬁed using RHGP versus siRN
Inﬂuenza RHGP Inﬂuenza
Hao et al., 2008.
Nature 454, 890
HIV
Brass et al., 2008
Science 319, 921
N4BP2
MRPL42 MRPL12
HERC6
SLC25A25, SLC30A9 SLC46A1
LSM4 LSM3
CSNK1D
COX5A COX6A1
RAD51L1
NDUFAF2, NDUFA7 NDUFB7
MDN1 MDN1
VPS34 (PIK3C3) VPS53
PKD2L2 PKD1L2
SF3A3
DDX17, DDX58 DDX42 and DDX28 DDX53, 55, 10, 3X
GRK6
AKT1 AKT1
LRRC16A LRRC8D
HEATR7A HEATR1
CHM
ADAM20 ADAM10
STXBP1
COG5 COG2, 3, 4
ZNF7 ZNF12
ARID1B
Shown is an assessment of targets and target families identiﬁed using RHGP (this report) o
published ﬁndings (as indicated). While four targets (MDN1, GRK6, AKT1 and STXBP1 in bold
have been linked with infection by different viruses. Not shown are the 87 additional targe
(please refer to Fig. 4 for a complete listing of the targets).identiﬁed in our RHGP-based screen, we recognized that it would be
impossible to validate all the targets. Therefore, a subset of targets
was selected to establish proof of concept. Duplex siRNAs were
generated for MRPL42, COX5A, TAPT1 and SLC25A25 and theseA approaches.
.
HIV
Konig et al., 2008.
Cell 135,49
WNV
Krishnan et al., 2008.
Nature 455, 242
Nedd4 NDFIP1
MRPL10
HERC1
SLC35A2 SLC39A11, SLS9A3 and SLC16A4
LSM8
CSNK2A1
COX6B2
RAD21 RAD51
VPS33A
SF3A1, SF3B1
DDX23
GRK6
CHML
STXBP1
ZNF148 ZNF214
ARID1A
r siRNA. This Table is limited to target families common to both the current study and
) were shared, the remainder were unique, though some related superfamily members
ts identiﬁed herein that had not commonality with previously-published information
Fig. 5. Validation of representative RHGP targets via siRNA targeting of HEK293 cells.
HEK 293 cells were transfected with the siRNAs speciﬁc for the human homologues of a
subset of targets listed in Fig. 4. The cells were infected with inﬂuenza virus A/Udorn/
72 at MOI of 1.0 and the progeny viruses were enumerated using a plaque formation
assay 48 h post-infection. Virus production is related to the negative control (Non-
targeting siRNA), which yielded 1.3×106 pfu/mL. Note that NP-1496 provides a positive
control for an established inﬂuenza siRNA target (see Ge et al., 2003).
478 B. Sui et al. / Virology 387 (2009) 473–481siRNAs were transfected into HEK293 cells (Fig. 5). Non-targeting
siRNAs provided a matched control for the transfection and a
reference standard. NP-1496 duplex siRNAs were synthesized and
provided a positive control. NP-1496 was selected based on a recent
report that siRNA targeting of NP-1496 efﬁciently decreases inﬂuenza
infection (Ge et al., 2003). Since inﬂuenza infection does not
efﬁciently kill HEK293 cells, we modiﬁed our experimental protocol
to measure viral titers (instead of host cell survival) as the primary
endpoint for efﬁcacy. The siRNA-treated HEK293 cells were infected
with A/Udorn/72 for 48 h and viral titers were measured by plaque
assays. As indicated in Fig. 5, MRPL42, COX5A, SLC25A35 or TAPT1
duplex siRNAs each decreased inﬂuenza virus production and at
levels comparable to the positive control (NP-1496 siRNAs). After
validating the ﬁndings using Udorn, we then extended the results to
other inﬂuenza viruses. For example, these siRNAs speciﬁcally also
blocked host cell killing by A/WSN/33, a different variant of
inﬂuenza (data not shown). Altogether, these ﬁndings validate the
application of RHGP to identify novel host-based targets and suggest
the potential for broad-spectrum application to different forms of
inﬂuenza.
Discussion
The major ﬁnding of our present study is the demonstration that
RHGP can provide an efﬁcient means to conduct genome-wide
screening for host factors that are required for inﬂuenza virus
infection. RHGP identiﬁed modiﬁcations that prevented inﬂuenza-
mediated killing of host cells including targets that have been
overexpressed or knocked down. We were able to validate these
targets using an inducible promoter within the RHGP vector to reverse
the phenotype, thereby minimizing the potential for spontaneous
artifacts that were not attributable to the RHGP strategy. This genome-
wide screen allowed us to identify 110 novel targets that render host
cells resistant to an otherwise lethal challenge with inﬂuenza virus. Of
these targets, most (106 of 110) had not been previously linked with
inﬂuenza. In addition, we ascribe novel functions to previously-
unknown genes and orfs. As proof of concept, a subset of targets was
further validated in independent studies using conventional siRNA
approaches.
One unique aspect of our present study is the use of an improved
form of RHGP. Previous studies with RHKO (Random Homozygous
Knockout), a precursor technology to RHGP, had employed MMLV-
based gene search vectors (GSVs) (Li and Cohen, 1996). The MMLV
technologies were intrinsically limited by low titers of GSV productionand this inefﬁciency limited the ability to conduct a thorough
assessment of the genome. We demonstrate for the ﬁrst time that a
lentiviral system (RHGP) overcomes these prior limitations. A
lentiviral vector also favors single-site insertion into actively-tran-
scribed genes (Mitchell et al., 2004), which further increases the
efﬁciency of the screening procedure.
RHGP is not biased by prior knowledge of the target. We analyzed
the human homologues of the remaining targets using the PANTHER
Classiﬁcation System (Mi et al., 2005) to identify putative biological
pathways. These targets could be broadly related to different
biological processes or molecular functions. Of the 99 targets available
for evaluation within the PANTHER system, 91 could be classiﬁed and
revealed 7 common biological processes and 8 major molecular
functions. Prominent among the biological processes were pathways
associated with nucleic acid and protein metabolism and intracellular
protein trafﬁcking (Fig. 6). The target functions included nucleic acid
binding, enzymatic activities (membrane trafﬁc proteins, kinases,
ligases, hydrolases), cell signaling and intracellular transport. It is
important to note that the assay utilized (cell survival following
inﬂuenza challenge) does not facilitate assessment of all cellular
genes. Speciﬁcally, this outcome precludes targets, where RHGP
perturbation of normal expression or function causes toxicity to the
host cell. Although this outcome limits the coverage of potential host
targets, we believe such an outcome is nonetheless desirable since it
might minimize potential targets that might be associated with toxic
side effects.
A recent series of siRNA-based studies identiﬁed host targets
associated with infection by inﬂuenza, HIV, or West Nile virus (see
Table 2 for summary) (Brass et al., 2008; Hao et al., 2008; Konig et al.,
2008; Krishnan et al., 2008). These earlier studies utilized host cells
that were derived from different species, which increases the
complexities of comparisons with our present ﬁndings. Compounding
this, siRNA is increasingly utilized for target discovery but is
intrinsically limited by the need for robust and sustained over-
expression of the siRNA. The outcomes of some siRNA ﬁndings have
also been clouded by questions of whether the siRNAs might non-
speciﬁcally alter host defense mechanisms (Kleinman et al., 2008),
which could be particularly problematic for applications of siRNA
technology to antiviral disease. RHGP might also induce potential
antiviral host defense mechanisms. For example, an antisense
orientation of the GSV is expected to induce double stranded RNA,
which itself can trigger host antiviral responses. Such a mechanism
could give rise to inherent resistance to inﬂuenza infection, particu-
larly when studying targets, where high levels of double stranded RNA
have accumulated. Such a response would not be expected to impact
situations, where the GSV inserts in a “Sense” orientation. With this in
mind, more than half of the inﬂuenza-resistant clones (56%) were
attributed to an antisense insertion of the GSV and we cannot exclude
that some of these antisense events might be subject to this
alternative explanation.
Most of the targets and pathways identiﬁed herein had not been
previously linked with inﬂuenza infection. This outcome likely
reﬂects the fact that RHGP can identify targets based on loss of
expression, overexpression of entire genes or overexpression of gene
domains. Some pathways identiﬁed herein had some relationship (in
terms of sequence, protein families or mechanistic pathways) with
host genes that had been linked with HIV or West Nile virus infection
(Brass et al., 2008; Konig et al., 2008; Krishnan et al., 2008). These
similarities may suggest different viral pathogens may share host
pathways. The genes identiﬁed herein are less similar to a recent
siRNA-based inﬂuenza study (Hao et al., 2008) (Table 2). We
postulate this difference may reﬂect the use of a Drosophila host
cell system in the earlier study as compared to a canine system
herein.
Our siRNA studies indicate that decreased expression of MRPL42,
COX5A, TAPT1 or SLC25A25 decreases susceptibility to inﬂuenza
Fig. 6. Classiﬁcation of the target genes by PANTHER Classiﬁcation System. Target genes that prevent inﬂuenza-mediated killing of host cells, as identiﬁed using RHGP, were classiﬁed
based on (A) established biological process or (B) molecular function. Note that the frequency of certain functions or processes (e.g., intracellular protein or membrane trafﬁcking)
exceeds that predicted by random chance as deﬁned using the frequency of genes with these functions in the human genome.
479B. Sui et al. / Virology 387 (2009) 473–481infection (Fig. 5). MRPL42 is a mitochondrial ribosomal protein
involved in mitochondrial protein synthesis. Although our current
evidence linking MRPL42 with inﬂuenza is novel, a recent study
indicated that introduction of SIV-Nef in CD4+ T cells stimulated
expression of related mitochondrial ribosomal proteins, MRPL1,
MRPL14 and MRPL19 (Ndolo et al., 2006). This outcome is intriguing
and may suggest common host mechanisms that are shared by HIV
and inﬂuenza. Likewise, COX5A is a component of the cytochrome C
oxidase (COX) complex and a different subunit, COX6A1, was recently
shown to regulate inﬂuenza replication (Hao et al., 2008). The
transmembrane protein TAPT1, which normally governs axial skeletal
patterning during development (Howell et al., 2007), can also
function as a cellular receptor for the human cytomegalovirus gH
receptor (Baldwin, Kleinberg, and Keay, 1996). The mechanistic basis
of TAPT1 in the regulation of inﬂuenza infection is currently unknown
andwill require additional investigation. Finally, members of the same
gene superfamily containing SLC25A25 reportedly regulate HIV (Brass
et al., 2008; Konig et al., 2008) and West Nile virus (WNV) (Krishnan
et al., 2008) infection.
Overexpression of some targets allowed MDCK cells to survive
inﬂuenza infection. Prominent among these are the B-cell CLL/
lymphoma 2 (BCL2) and plasminogen activator, urokinase (PLAU)
genes. The proto-oncogene, BCL2, is a well-characterized regulator of
cell survival and BCL2 regulates cell survival during infection by
Sindbis (Levine et al., 1993), inﬂuenza (Hinshaw et al., 1994) or HIV-1(Mishra et al., 2007) viruses. Likewise, the amino-terminal fragment
of PLAU was recently shown to suppress the assembly and budding of
HIV-1 from infected cells (Wada et al., 2001). PLAU and its receptor
have also been linked with the regulation of infection by human
respiratory syncytial virus (Martinez et al., 2007).
Although these studies provide compelling new information, it is
important to appreciate that cell culture-based information may not
necessarily translate into new therapeutics. For example, transgenic
mouse studies demonstrate that homozygous knock-out of TAPT1
results in embryonic lethality (Howell et al., 2007), which may
indicate that such targets may not be suitable for safe therapeutic
intervention. Future investigationwill be necessary to extrapolate our
present ﬁndings with cell-based studies to work with more complex
systems. Nonetheless, the work described above may provide new
insight into new opportunities for future host-based therapeutic
targeting.
Materials and methods
Chemicals and cell culture
MDCK cells, human 293HEK cells and MEM medium were
purchased from the American Type Culture Collection (ATCC).
Inﬂuenza virus A/Udorn/72 was purchased from Charles River Lab.
All siRNA oligonucleotides were synthesized by Dharmacon Research.
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stable cell lines
The pTet-Off transactivator vector was constructed using pIRE-
Shyg3 (Clontech) as a backbone. A PCR-generated tTA fragment was
inserted into the BamHI and SofI sites of the pIREShyg3 vector to
generate the pTet-Off transactivator vector, pIREShyg3-tTA.
To createMDCK/Tet-Off cell lines, 2×106MDCK cells were cultured
in 10 cm plates and transfected with 10 μg pIREShyg3-tTA vector using
Fugene 6 (Roche). Twenty-four hours post-transfection, log-phase
cultures of MDCK cells selected using 200 μg/mL hygromycin and the
medium was changed every 3 days until all controls cells were killed.
Hygromycin resistant clones were screened for the Doxycylcine (Dox;
Invitrogen) induction activity using pTRE-luc (Clontech) vector and
the Bright-Glo luciferase assay kit (Promega). Stable clones with at
least 40-fold induction were used to create RHGP libraries.
Construction of the RHGP gene search vector, pRHGP22
The RHGP gene search vector, pRHGP22 was constructed using the
pLEST vector as a backbone (provided by Dr. Stanley Cohen, Stanford)
(Lu et al., 2004). The pTRE-Tight-CMV-BlasticidinR was substituted as
the promoter. The 3′ UTR WPRE element was removed and the p15A
ori-Chloramphenicol acetyltransferase (CAT) resistant gene was
inserted at the same site. Two LoxP sites were inserted downstream
from the BlasticidinR gene and upstream from the p15A ori-CAT,
respectively.
Production of RHGP virus and Construction of RHGP libraries
RHGP lentiviruses were produced using ViroPower Expression
System (Invitrogen). HEK293FT cells were plated in 10 cm plates at
106 cells per plate. After 24 h incubation, the cells were transfected
with 3 μg RHGP22 and 9 μg ViroPower Packaging Mix using
Lipofectimine 2000 (Invitrogen). The medium was changed after 5 h
incubation at 37 °C. After 48 h, viruses in the culture medium were
ﬁltrated through a 0.45 μm ﬁlter and tittered according to the
manufacturer's instruction.
To construct the RHGP library, MDCK/Tet-off cells were plated in
15 cm plates at 2×106 cells per plate. The next day, the samples were
washed with PBS and transduced with RHGP viruses in 6 μg/mL
polybrene. The samples were incubated at 37 °C for 2 h with mixing
prior to replacement with fresh media. Forty eight hours post-
transduction, the cells were washed with PBS and infected with
inﬂuenza virus A/Udorn/72 at a multiplicity of infection (MOI) of 0.1
for 2 h in DMEM medium containing 0.2% BSA, 200 μg/mL
hygromycin, 2 μg/mL bovine trypsin and 6 μg/mL Blasticidin with
gentle mixing every 15 min. The media was then replenished with
MEM. After two days, the cells were washed with PBS and infected
again with inﬂuenza virus as indicated above. After the second round
of infection, the samples were washed with PBS and incubated in
conditioning media containing 200 μg/mL hygromycin and 6 μg/mL
blasticidin. The medium was changed every 3 days until all non-
transduced cells were killed and the virus resistant colonies had
formed. Two weeks after second round of infection, the visible
individual colonies were isolated and subcultured in 24-well plates.
Reversibility assay for inﬂuenza virus resistant cell clones
To verify reversibility of RHGP event, the MDCK/Tet-Off cells were
cultured in absence or presence of Dox for 3 days. The cells were
plated in 10 cm plates at 2×106 cells per plate and cultured with or
without Dox. After 24 h, the samples were infected with inﬂuenza
virus A/Udorn/72 at MOI of 1×10-1 and 1×10−5, respectively. After
3 days, surviving cells were stained with crystal violet to visualize the
remaining cells.Identiﬁcation of the candidate genes from inﬂuenza virus resistant clones
1×106 cells from each clone were suspended in lysis buffer
containing 0.32 M Sucrose, 10 mM Tris pH 7.5, 5 mM MgCl2 and 1%
Triton X-100. The lysate was centrifuged at 1500×g for 15min and the
pellet was treated with 100 μg of proteinase K (Sigma) in proteinase K
buffer containing 25 mM EDTA, 150 mM NaCl and 40 mM Tris, 0.5%
SDS, pH 7.5. The mixture was incubated overnight at 37 °C, treated
with 50 μg RNase A (Sigma) and incubated at 37 °C for 2 h. Genomic
DNAwas extracted with phenol/isoamyl alcohol/chloroform followed
by precipitation with isopropanol. The DNA pellet was washed with
70% ethanol and dissolved in TE buffer (pH 7.5).
Genomic DNA (10 μg) was digestedwith restriction enzyme BamHI
or XbaI, extracted with phenol/isoamyl alcohol/chloroform, precipi-
tated with ethanol and dissolved in TE buffer. Digested DNA (2.5 μg)
was self-ligated overnight using T4 ligase (Invitrogen) at 16 °C. The
ligated DNA was precipitated with ethanol and washed with 70%
ethanol. The DNA pellet was dissolved in TE buffer and electroporated
into DH10B ElectroMax competent cells (Invitrogen). Multiple
colonies were isolated for plasmid DNA preparation and restriction
enzyme digestion. The plasmid DNA was further used to identify the
target genes by DNA sequencing and genome mapping.
Validation of host target genes with siRNA
The human duplex siRNA homologues for candidate gene MRPL42,
COX5A, SLC25A25 and TAPT1 were prepared as recommended by the
manufacturer. The siRNA NP-1496 sequence (GGAUCUUAUUUCUUCG-
GAGUU), which targets the nucleocapsid (NP) gene of inﬂuenza virus,
provided a positive control (Ge et al., 2003). Non-targeting siRNA,
siCONTROL1 provided a negative control. HEK293 cells were plated in
24-well plates at 1×105 cells per well, respectively. After 24 h
incubation, the cells were transfected with 20 nM of siRNA and
TransIT-TKO, according to the manufacturer's instruction (Mirus). The
cells were re-transfected with siRNA after 24 h incubation. Twenty-
four hours after second round of transfection, the samples were
washed with MEM followed by infection with inﬂuenza virus A/
Udorn/72 (MOI 1). The cells were incubated for 1 h with gentle
rocking every 15 min. The culture medium from each well was
collected 48 h post-transfection and progeny viruses in the medium
were titrated using standard plaque assays.
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